Every material Form 8-K Kiniksa Pharmaceuticals International, plc has filed with the SEC since July 28, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Kiniksa reported third-quarter 2026 total revenue of $286.0 million, up from $180.9 million a year earlier, and net income of $47.3 million, compared with $18.4 million. The company raised its 2026 ARCALYST net product revenue expectation to $1.045 billion to $1.050 billion, from $980 million to $995 million previously, and expects its current operating plan to remain cash flow positive on an annual basis.
Q3 2026 revenue was $286.0 million, compared with $180.9 million in Q3 2025.
Q3 2026 net income was $47.3 million, or $0.56 per diluted share, compared with $18.4 million, or $0.23 per diluted share, a year earlier.
2026 ARCALYST net product revenue guidance was raised to $1.045 billion to $1.050 billion from $980 million to $995 million.
As of September 30, 2026, the company had $568.8 million in cash, cash equivalents and short-term investments and no debt.
Kiniksa Pharmaceuticals appointed Ross Moat as President and Chief Operating Officer, effective immediately, with Mr. Moat continuing to report to Chairman and CEO Sanj K. Patel. Effective January 1, 2027, his base salary and target bonus will rise to $700,000 and 60% from $650,000 and 55%, a change that signals a larger operating role but carries no financial results.
Ross Moat appointed President and Chief Operating Officer on October 17, 2026, effective immediately
Mr. Moat has been with the company since June 2019 and most recently served as EVP, Chief Operating Officer
Base salary rises to $700,000 from $650,000; target bonus rises to 60% from 55%, both effective January 1, 2027
Kiniksa reported second quarter 2026 total revenue of $243.6 million, up from $156.8 million a year earlier, and net income of $25.4 million, up from $17.8 million. The company raised its 2026 ARCALYST net product revenue guidance to $980 million to $995 million, from $930 million to $945 million, which signals higher expected sales for the main product.
Q2 2026 total revenue was $243.6 million, compared with $156.8 million in Q2 2025.
Q2 2026 net income was $25.4 million, or $0.30 per diluted share, compared with $17.8 million, or $0.23 per diluted share, in Q2 2025.
2026 ARCALYST net product revenue guidance raised to $980 million to $995 million from $930 million to $945 million.
Cash, cash equivalents, and short-term investments were $525.9 million as of June 30, 2026, and the company had no debt.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Kiniksa Pharmaceuticals International, plc filing is on SEC EDGAR ↗. 8-K briefs of other companies →